Entity
  • Carthera

    Created in 2010
  • BETA

    Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups
  • Social networks

    547 4,981
  • Activities

  • Technologies

  • Entity types

  • Location

    1 Pl. Vaclav Havel, 69007 Lyon, France

    Lyon

    France

  • Employees

    Scale: 2-10

    Estimated: 27

  • SIREN

    520004607
  • Engaged corporates

    24
    11 13
  • Added in Motherbase

    5 years, 7 months ago
Description
  • Value proposition

    Advanced Brain Therapy

    Carthera® is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of severe brain disorders.

    Carthera® has developed a proprietary device called SonoCloud®- a groundbreaking medical device that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain.

    By using SonoCloud®, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases: oncology indications (glioblastoma, brain metastasis) or neurodegenerative diseases (such as Alzheimer’s Disease, ALS).

    The products developed by Carthera® are in clinical or preclinical evaluation (not FDA or CE approved) and are not available for sale.

    Medical Devices, Neurosurgery, Therapeutic Ultrasound, and Neuro-oncology

  • Original language

    Advanced Brain Therapy

    Carthera® is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of severe brain disorders.

    Carthera® has developed a proprietary device called SonoCloud®- a groundbreaking medical device that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain.

    By using SonoCloud®, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases: oncology indications (glioblastoma, brain metastasis) or neurodegenerative diseases (such as Alzheimer’s Disease, ALS).

    The products developed by Carthera® are in clinical or preclinical evaluation (not FDA or CE approved) and are not available for sale.

Corporate interactions BETA
Corporate TypeTweets Articles
Institut Curie
Institut Curie
Health, Hospitals and Health Care
Institut Curie
Health, Hospitals and Health Care
Not capitalistic
Partnership
Not event

17 Feb 2023


Gustave Roussy
Gustave Roussy
Health, Hospitals and Health Care
Gustave Roussy
Health, Hospitals and Health Care
Other

17 Feb 2023


Estimeo
Estimeo
Consulting, Information Services
Estimeo
Consulting, Information Services
Other

3 Jul 2023


BFM Business
BFM Business
Media, Broadcast Media Production and Distribution
BFM Business
Media, Broadcast Media Production and Distribution
Other

3 Jul 2023


Région Auvergne-Rhône-Alpes
Région Auvergne-Rhône-Alpes
National and local authorities, Government Administration
Région Auvergne-Rhône-Alpes
National and local authorities, Government Administration
Other

7 Jul 2023


La French Tech Saint-Etienne Lyon
La French Tech Saint-Etienne Lyon
French Tech, IT Services and IT Consulting
La French Tech Saint-Etienne Lyon
French Tech, IT Services and IT Consulting
Other

11 Jul 2023


Lyonbiopôle Auvergne-Rhône-Alpes
Lyonbiopôle Auvergne-Rhône-Alpes
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
Lyonbiopôle Auvergne-Rhône-Alpes
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
Other

5 Mar 2020

15 Nov 2023



Avolta
Avolta
Finance, Investment Banking
Avolta
Finance, Investment Banking
Other

15 Dec 2023


Sifted
Sifted
Newspaper Publishing
Sifted
Newspaper Publishing
Other

15 Jan 2024


France Biotech
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
Not capitalistic
Not partnership
Event

1 Mar 2024


Similar entities
Loading...
Loading...
Social network dynamics